Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Senseonics stock logo

1. Senseonics NYSE:SENS

$0.41 -0.02 (-4.09%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about Senseonics

Market Capitalization
$331.58 million
P/E Ratio
-3.13
Consensus Rating
Buy
Consensus Price Target
$1.54 (+278.7% Upside)
Volume
5.59 million shares
Average Volume
8.14 million shares
Plus Therapeutics stock logo

2. Plus Therapeutics NASDAQ:PSTV

$0.62 +0.00 (+0.47%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus Therapeutics

Market Capitalization
$61.24 million
P/E Ratio
-0.28
Consensus Rating
Buy
Consensus Price Target
$8.00 (+1,196.6% Upside)
Volume
4.16 million shares
Average Volume
20.75 million shares
Adicet Bio stock logo

3. Adicet Bio NASDAQ:ACET

$0.98 -0.06 (-5.48%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$82.33 million
P/E Ratio
-0.75
Consensus Rating
Moderate Buy
Consensus Price Target
$5.67 (+476.5% Upside)
Volume
1.62 million shares
Average Volume
818,236 shares
Reviva Pharmaceuticals stock logo

4. Reviva Pharmaceuticals NASDAQ:RVPH

$0.59 +0.00 (+0.75%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva Pharmaceuticals

Market Capitalization
$40.98 million
P/E Ratio
-0.91
Consensus Rating
Moderate Buy
Consensus Price Target
$4.86 (+720.5% Upside)
Volume
4.19 million shares
Average Volume
3.59 million shares
Immunic stock logo

5. Immunic NASDAQ:IMUX

$0.80 -0.01 (-1.70%)
As of 03:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about Immunic

Market Capitalization
$79.12 million
P/E Ratio
-0.85
Consensus Rating
Moderate Buy
Consensus Price Target
$9.50 (+1,084.5% Upside)
Volume
1.44 million shares
Average Volume
1.29 million shares
IceCure Medical stock logo

6. IceCure Medical NASDAQ:ICCM

$0.82 -0.01 (-1.17%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. More about IceCure Medical

Market Capitalization
$55.92 million
P/E Ratio
-5.09
Consensus Rating
Moderate Buy
Consensus Price Target
$2.64 (+222.9% Upside)
Volume
471,822 shares
Average Volume
973,156 shares
Adial Pharmaceuticals stock logo

7. Adial Pharmaceuticals NASDAQ:ADIL

$0.36 -0.01 (-3.60%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. More about Adial Pharmaceuticals

Market Capitalization
$7.82 million
P/E Ratio
-0.34
Consensus Rating
Moderate Buy
Consensus Price Target
$4.75 (+1,223.1% Upside)
Volume
222,662 shares
Average Volume
3.42 million shares
Century Therapeutics stock logo

8. Century Therapeutics NASDAQ:IPSC

$0.55 -0.01 (-2.12%)
As of 03:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century Therapeutics

Market Capitalization
$47.00 million
P/E Ratio
-1.88
Consensus Rating
Moderate Buy
Consensus Price Target
$3.75 (+588.1% Upside)
Volume
354,042 shares
Average Volume
710,798 shares
Promis Neurosciences stock logo

9. Promis Neurosciences NASDAQ:PMN

$0.44 -0.02 (-5.06%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. More about Promis Neurosciences

Market Capitalization
$23.95 million
P/E Ratio
-2.12
Consensus Rating
Moderate Buy
Consensus Price Target
$4.33 (+878.2% Upside)
Volume
367,958 shares
Average Volume
2.65 million shares
Carisma Therapeutics stock logo

10. Carisma Therapeutics NASDAQ:CARM

$0.04 0.00 (-0.94%)
As of 03:03 PM Eastern

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More about Carisma Therapeutics

Market Capitalization
$1.76 million
P/E Ratio
-0.03
Consensus Rating
Moderate Buy
Consensus Price Target
$1.93 (+4,472.4% Upside)
Volume
464,497 shares
Average Volume
7.48 million shares
Sangamo Therapeutics stock logo

11. Sangamo Therapeutics NASDAQ:SGMO

$0.64 -0.01 (-1.07%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More about Sangamo Therapeutics

Market Capitalization
$192.79 million
P/E Ratio
-2.20
Consensus Rating
Hold
Consensus Price Target
$4.50 (+605.3% Upside)
Volume
4.23 million shares
Average Volume
5.88 million shares
Atossa Genetics stock logo

12. Atossa Genetics NASDAQ:ATOS

$0.97 -0.06 (-5.53%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. More about Atossa Genetics

Market Capitalization
$125.55 million
P/E Ratio
-4.23
Consensus Rating
Hold
Consensus Price Target
$6.25 (+542.3% Upside)
Volume
1.07 million shares
Average Volume
887,237 shares
BARK stock logo

13. BARK NYSE:BARK

$0.80 +0.03 (+3.56%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BARK Inc, a dog-centric company, provides products, services, and content for dogs. It operates in two segments, Direct to Consumer and Commerce. More about BARK

Market Capitalization
$136.08 million
P/E Ratio
-4.71
Consensus Rating
Hold
Consensus Price Target
$2.63 (+228.5% Upside)
Volume
949,544 shares
Average Volume
1.01 million shares
Assertio stock logo

14. Assertio NASDAQ:ASRT

$0.80 -0.02 (-2.92%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. More about Assertio

Market Capitalization
$76.99 million
P/E Ratio
-1.78
Consensus Rating
Hold
Consensus Price Target
$2.38 (+196.9% Upside)
Volume
106,427 shares
Average Volume
316,454 shares
IO Biotech stock logo

15. IO Biotech NASDAQ:IOBT

$0.67 -0.10 (-12.42%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. More about IO Biotech

P/E Ratio
-0.42
Consensus Rating
Hold
Consensus Price Target
$8.00 (+1,092.3% Upside)
Volume
1.92 million shares
Average Volume
1.64 million shares
Today's Range
$0.62
$0.79
PLAYSTUDIOS stock logo

16. PLAYSTUDIOS NASDAQ:MYPS

$0.94 0.00 (-0.01%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PLAYSTUDIOS, Inc develops and publishes free-to-play casual games for mobile and social platforms in the United States and internationally. More about PLAYSTUDIOS

Market Capitalization
$117.95 million
P/E Ratio
-3.92
Consensus Rating
Hold
Consensus Price Target
$2.50 (+165.7% Upside)
Volume
190,051 shares
Average Volume
231,967 shares
Agilon Health stock logo

17. Agilon Health NYSE:AGL

$0.95 -0.01 (-1.17%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. More about Agilon Health

Market Capitalization
$395.36 million
P/E Ratio
-1.24
Consensus Rating
Hold
Consensus Price Target
$2.81 (+194.3% Upside)
Volume
5.55 million shares
Average Volume
7.15 million shares
Adaptimmune Therapeutics stock logo

18. Adaptimmune Therapeutics NASDAQ:ADAP

$0.20 +0.01 (+4.51%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More about Adaptimmune Therapeutics

Market Capitalization
$53.81 million
P/E Ratio
-0.31
Consensus Rating
Reduce
Consensus Price Target
$1.35 (+562.6% Upside)
Volume
31.74 million shares
Average Volume
32.47 million shares
Rallybio stock logo

19. Rallybio NASDAQ:RLYB

$0.54 -0.02 (-2.87%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More about Rallybio

Market Capitalization
$22.48 million
P/E Ratio
-0.57
Consensus Rating
Reduce
Consensus Price Target
$5.00 (+829.4% Upside)
Volume
97,955 shares
Average Volume
1.03 million shares
Exro Technologies stock logo

20. Exro Technologies OTCMKTS:EXROF

$0.02 0.00 (0.00%)
As of 10/16/2025

Exro Technologies Inc focuses on developing generation power-control electronics in Canada. The company offers Exro Coil Driver, which allows the motor to switch between different operational profiles in real-time, as well as have multiple gears for scooters, electric bikes, recreational, light electric cars, motorcycles, fleet vans, electric buses, passenger vehicles, long-haul trucks, and industrial vehicles markets; and Exro Cell Driver, a stationary energy storage system for commercial and industrial energy storage applications. More about Exro Technologies

Market Capitalization
$9.97 million
P/E Ratio
-0.04
Consensus Rating
Reduce
Today's Range
$0.0174
$0.0174
50-Day Range
$0.01
$0.06
52-Week Range
$0.01
$0.38
Beyond Meat stock logo

21. Beyond Meat NASDAQ:BYND

$0.65 +0.13 (+25.19%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Beyond Meat, Inc, a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. More about Beyond Meat

Market Capitalization
$50.04 million
P/E Ratio
-0.30
Consensus Rating
Strong Sell
Consensus Price Target
$2.27 (+248.2% Upside)
Volume
378.72 million shares
Average Volume
7.82 million shares